JP Morgan Chase’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,058,899
| Closed | -$36.4M | – | 6178 |
|
|
2020
Q3 | $36.4M | Buy |
1,058,899
+905,466
| +590% | +$19.3M | 0.01% | 1138 |
|
|
2020
Q2 | $2.56M | Buy |
153,433
+50,144
| +49% | +$851K | ﹤0.01% | 2931 |
|
|
2020
Q1 | $1.49M | Sell |
103,289
-15,411
| -13% | -$394K | ﹤0.01% | 3154 |
|
|
2019
Q4 | $3.97M | Sell |
118,700
-10,015
| -8% | -$280K | ﹤0.01% | 2871 |
|
|
2019
Q3 | $2.7M | Buy |
128,715
+6,787
| +6% | +$139K | ﹤0.01% | 3210 |
|
|
2019
Q2 | $2.43M | Sell |
121,928
-6,706
| -5% | -$138K | ﹤0.01% | 3248 |
|
|
2019
Q1 | $2.88M | Sell |
128,634
-16,952
| -12% | -$399K | ﹤0.01% | 3073 |
|
|
2018
Q4 | $3.48M | Sell |
145,586
-380
| -0.3% | -$9.83K | ﹤0.01% | 2855 |
|
|
2018
Q3 | $3.98M | Buy |
145,966
+9,289
| +7% | +$263K | ﹤0.01% | 2925 |
|
|
2018
Q2 | $3.67M | Sell |
136,677
-6,074
| -4% | -$186K | ﹤0.01% | 2934 |
|
|
2018
Q1 | $4.54M | Sell |
142,751
-18,858
| -12% | -$664K | ﹤0.01% | 2662 |
|
|
2017
Q4 | $6.11M | Sell |
161,609
-132,796
| -45% | -$4.28M | ﹤0.01% | 2516 |
|
|
2017
Q3 | $7.24M | Sell |
294,405
-48,352
| -14% | -$1.04M | ﹤0.01% | 2263 |
|
|
2017
Q2 | $7.05M | Buy |
342,757
+79,225
| +30% | +$1.51M | ﹤0.01% | 2236 |
|
|
2017
Q1 | $5.73M | Sell |
263,532
-32,655
| -11% | -$670K | ﹤0.01% | 2340 |
|
|
2016
Q4 | $6.06M | Buy |
296,187
+113,537
| +62% | +$2.32M | ﹤0.01% | 2292 |
|
|
2016
Q3 | $2.74M | Buy |
182,650
+76,675
| +72% | +$1.03M | ﹤0.01% | 2612 |
|
|
2016
Q2 | $1.15M | Buy |
105,975
+63,675
| +151% | +$865K | ﹤0.01% | 3105 |
|
|
2016
Q1 | $574K | Buy |
+42,300
| New | +$660K | ﹤0.01% | 3305 |
|
JP Morgan Chase's AIMT Position: Q4 2020 in Review
JP Morgan Chase sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 1,058,899 shares — an estimated $36.4M sold.
JP Morgan Chase first reported a position in AIMT in Q1 2016 and held it in 19 quarters. The position peaked at $36.4M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- JP Morgan Chase reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- JP Morgan Chase sold 1,058,899 Aimmune Therapeutics shares in Q4 2020, an estimated $36.4M.
- JP Morgan Chase first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 19 quarters.
- JP Morgan Chase's Aimmune Therapeutics position peaked at $36.4M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.